Holmes Report 03 Jul 2017 // 6:40AM GMT
CAMBRIDGE — Biogen has appointed Catherine Steele senior vice president of corporate affairs. Steele has over 25 years of public affairs experience and will lead the company's product, corporate, and internal communications as well as government affairs and patient advocacy efforts. Prior to this role, Steele served as global yea, communications and patient relations at Novartis Pharmaceuticals, where she was responsible for corporate reputation and helping drive external, internal and executive communication strategies.
CHICAGO — Performance based education organization School of Rock has appointed Rob Price as president and chief executive officer. He will work closely with School of Rock's senior leadership team to enhance the student experience at each school, expand the global footprint, and establish creative partnerships to maximize the brand's reach. Prior to this, Price served as president at Edible Arrangements. He has also held an executive role at Wawa Foods Markets and H-E-B- Grocery.
NEEDHAM — Private real estate investment, development and management firm Bulfinch Companies has announced that Katherine F. Shoss has joined the team as vice president, director of marketing. In her new role, Shoss is responsible for strengthening awareness of the brand and its portfolio of properties within Greater Boston through the strategic implementation of traditional and digital channels for brand engagement and visibility. Prior to this, Shoss was director of marketing an senior associate at Architectural Resources Cambridge (ARC), an architecture firm where she worked for over a decade.
VANCOUVER — BiOasis Technologies has named Catherine London executive vice president, head of corporate communications and investor relations. She will report to Dr. Mark Day, president and chief executive officer of BiOasis. In this newly created position, London will be responsible for leading all external communications, corporate visibility, brand building, reputation management, financial communications and investor relations. She has more than 22 years experience in pharmaceutical and healthcare and had led large, global teams and strategic plans.